Diversified Portfolio The merger yields a blended portfolio with a strong U.S. generics presence and a growing branded biosimilars franchise, creating cross sell opportunities across distributors, hospitals, and health systems. Position to offer bundled contracts and lifecycle solutions that leverage both generics and branded assets.

Capacity Expansion Significant investments in North Bellport and Attleboro facilities, along with workforce expansion, signal scalable capacity and improved supply security. Ideal for long term supply agreements, toll manufacturing partnerships, and expanded geographic coverage with key customers.

MA Growth Recent acquisitions and product approvals broaden therapeutic capabilities into new areas and biosimilars, enabling partnerships around lifecycle management, specialty injectables, and market access strategies.

Tech Enablement A modern tech stack supports data driven planning, governance, and analytics to optimize supply chain operations and customer collaboration, creating opportunities for analytics services, forecasting improvements, and digital engagement with partners.

Affordability Focus Commitment to affordability and accessible medicines positions the company for payer and provider focused discussions, offering pricing models and patient access programs that align with value based procurement and budget containment.